Contract research news in brief
pharmafile | October 26, 2009 | News story | Research and Development | cros
Pharmafocus' round-up of contract research news includes ICON's Q3 results, expansion plans at ClinTec and a prestigious award for Bilcare
Irish contract clinical research specialist ICON plc saw its revenue dip 2.3% in the third quarter of 2009 to $220 million, but managed to raise its income from operations by 12% to $30.4 million "despite the economic and industry headwinds", according to chief executive Peter Gray. Like many of its peers in the industry ICON saw its business held back by high levels of project cancellations, but said "the levels of business opportunity continue to be strong". ICON has raised its earnings per share guidance for the full-year to $1.48-$1.52.
Scottish CRO ClinTec International has expanded on the international stage via the opening of a new office in Cairo, Egypt. The company said the move "consolidates [our] reputation as a major presence in the Middle East and North Africa (MENA) region", which it says is growing quickly and represents a market worth around $10 billion. ClinTec already operates in 40 countries around the world.
Indian contract service organisation Bilcare has won the 2009 European Outsourcing Award at the Conference on Pharmaceutical Ingredients (CPhI), held in Madrid, Spain, for the second year in succession.
The UK's Institute of Clinical Research says it is responding to a recent increase in clinical researchers going freelance by launching a new training course to help them find their feet. The course – entitled Starting a Business as a Freelancer – will take place on 4 November. More details are available here.
China's WuXi Pharmatech has appointed Dr Hui Cai as vice president of business development, reporting directly to Dr Richard Soll, senior vice president of the firm's Integrated Services division. Cai was formerly president of life science consultancy firm Inflexion BioPartners.
MPI Research, a CRO specialising in preclinical studies, has won a contract from
development company Kineta for a project developing immune system-modulating therapies. The aim is to advance first drug candidates into clinical trials in 2010.
US cardiovascular research specialist Medpace will run the phase III programme for Amarin's triglyceride-lowering drug AMR101 under the terms of a new agreement signed between the two firms. Medpace will run two studies, in hypertriglyceridaemia and mixed dyslipidaemia respectively – aimed at securing US approval for the product in 2012.
a2a_linkname=”Pharmafocus”;a2a_linkurl=”http://www.pharmafocus.com”;a2a_num_services=6;a2a_prioritize=[”twitter”,”linkedin”,”facebook”,”delicious”,”friendfeed”,”stumbleupon”,”reddit”];
Related Content
Clinical Trial Success: How Relationships Are Key
Jeffrey Zucker, Vice President of Feasibility and Recruitment Optimisation at Worldwide Clinical Trials, offers strategies …
Pharma outsourcing: CROs, CMOs and external collaboration
Thirty years ago pharma companies seemed to use external contractors as a sort of fire …
Careers in next generation contract partnering
Over the past few years, a significant shift has occurred in the depth and type …
